🚨🚨🚚🚛🚨🚨email from Robert Hardy @RobHardyFR8 whose Customs Clearance Consortium is part of govt’s £200m scheme for GB-NI border warns of “huge shortage” of customs agents. Via @SJAMcBride /1

https://t.co/WoLWdI8LoF

Good to see @Marthakearney on @BBCr4today taking @pritipatel to task over the numbers of lorries in Dover - now 1,500 in Stack (M20) and Manston airfield combined - rather more than 170 that @BorisJohnson said yesterday, baffling haulage groups /1

@BBCr4today @pritipatel @BorisJohnson She won't say whether lorry drivers will have to take a PCR test (long-winded, requires RNA extraction etc. 24-48hrs) rather than much faster (and less sensitive) lateral flow test. Short Strait will struggle to operates with PCR tests. You'd need one yesterday for tomorrow! /2

@BBCr4today @pritipatel @BorisJohnson Because of the delays that have empty lorries already stuck in the queues, in an earlier interview British Retail Consortium @the_brc Andrew Opie said fresh food shortages would occur within days because lorries couldn't get back to Spain etc to reload /3

@BBCr4today @pritipatel @BorisJohnson @the_brc Haulage experts like @RHADuncanB are always at pains to explain that the lorries at Dover (and GB-IE, for that matter) are flowing in a continuous cycle. More than 85% are from EU countries. So if you block one side, or artery the whole system starts to grind to a halt/4

@BBCr4today @pritipatel @BorisJohnson @the_brc @RHADuncanB This episode has been a bit of a teaching moment, exposing the canard that the UK can unilaterally "take back control of its borders". It can't. Borders are membranes. Traffic flows in both directions. Actions by one side impact the other - as French move has demonstrated. /5

🚨🚨🚨🇪🇺🇬🇧🚛🚒🇪🇺🇬🇧🚨🚨🚨 serious #brexit story alert - companies now starting to see penny drop on what rules of origin does to supply chains (food for example) but Brussels seems deaf to both EU & U.K. pleading. A bellwether? 😬 Stay with me. 1/


So first the problem: its a tad complicated but basically goods that are imported into UK and then 'hubbed' onwards into Ireland or other parts of the EU are facing full EU tariffs - this is particularly bad for food stuffs, which attract high tariffs. Why is this? /2

It's a function of the Rules of Origin clauses that mean that goods have to sufficiently "originate" in the UK to qualify for zero-tariff entry to EU (and vice versa).

But to qualify, you have to do something to the goods - process them or add value - not just punt them on /3

The brilliant @AnnaJerzewska does a better job than me of explaining, but the important thing is that this is a nightmare for companies that 'hub' /distribute products through the UK - and that's both EU and UK companies /4

So both the @Foodanddrinkfed and EU groups like @CAOBISCO_EU (chocs etc) say they want the EU Commission to fix this with a derogation/waiver that takes into account proximity and interdependence of EU/UK supply chains. /5

1/x Since I promised a few investors outside Sweden/Nordics to look deeper into $CDON, with my negative customer biases aside, here's a short thread;

Let's first go through the negatives

2/x I really understand the excitement when you put on the "local dominant marketplace"-glasses and start comparing CDON multiples to the likes of $AMZN, $MELI, $SE or whatever. But with boots on the ground I can assure you, that they are *nothing* of the sort. At least yet.

3/x Just looking at GMV/revenue, after >20y in business, an "everything store", CDON doesn't even come near other local niche players like $BHG (8bSEK) or $BOOZT (4bSEK) and other private companies. They are closer to $LYKO in size, who are only selling hair & beauty..

4/x Unfortunately the brand is very much on decline (especially among young ppl) since the website has been mistreated for years and years, so I think they have to work extremely hard on building trust + enhance customer experience to even have a change long term.

5/x Like I wrote yesterday we have a very divided (in a good way) eCommerce market in the Nordics, with lots of amazing niche players with top notch customer experience. To put it in words you understand, we are a more $SHOP like region with independent businesses.

1/ My most popular tweets of 2020 by month (thread)

January:

A reminder of @morganhousel cash strategy.

For every $1,000 in cash:

More: ⬇️⬇️⬇️⬇️⬇️

2/ February

If you've truly found the next $AMZN, $AAPL, or $NFLX and can hold for years, it's nearly impossible to overpay.

But finding them is hard.

3/ March

Millennials have seen tech crash, 2008, and now #COVID19

I'm worried that many of them will swear off the stock market -- the greatest wealth-building device ever -- for life.

4/ April

Want to see the checklists used by

Buffet
Dalio
Fischer
Graham
Greenblatt
Klarman
Marks
Munger

and

5/ May

When the P/E ratio is:

Useless (Stage 1, 4) - $MDB, $SHOP, $PINS, $GME, $JCP

Semi-useful (Stage 2) - $TTD, $NFLX

Useful! (Stage 3) - $MSFT, $AAPL, $V

In determining valuation

Anyone have any opinions on how self-insured employers consider innovative healthcare offerings to pass on to their employees?

As I understand it, by shouldering the financial risk, self-insured employers can curate a list of more relevant benefits ... (1/10)

... thereby avoiding paying out lofty insurance premiums for services that its employees don't use or want. There seems to be a long list of intangible benefits having to do with talent acquisition and retention, but I'd like to understand the cost equations more fully. (2/10)

In the context of multi-cancer screening, I'm skeptical that it could be cost-saving for small or medium-sized employers (<500 employees). Assuming a representative sample of the population, there are simply too few cancers and too many false positives w/ expensive ... (3/10)

... diagnostic follow-ups to bend the unit-economics in the right direction. Indeed, for larger self-insured employers, maybe on the order of thousands of employees, the dynamics may change. Each true positive is a chance to save on treatment cost and (possibly) to ... (4/10)

... extend life. However, employers won't likely be able to distinguish between true life-extension and lead-time bias without prospective, randomized studies, which are due out in the 2024-25 timeframe. Still, these likely will include interim endpoints only. (5/10)